文献速递呼吸道感染呼吸危重症与机械通气

无氧疗天数作为COVID-19及其他新发低氧血症治疗临床试验的结局指标

Oxygen-Free Days as an Outcome Measure in Clinical Trials of Therapies for COVID-19 and Other Causes of New-Onset Hypoxemia.
PubMed 文献 · Chest · 2022-04-30

本文提出无氧疗天数(OFDs)作为急性肺损伤临床试验的新型复合结局,整合死亡与新发补充氧疗持续时间,旨在捕捉以患者为中心的恢复结局。OFDs为ACTIV-4 Host Tissue平台的主要结局,用于评估住院COVID-19伴新发低氧血症成人的宿主反应靶向治疗。文章阐述OFDs的理论依据、标准化定义与分析方法及样本量计算框架。

要点

  • OFDs整合死亡与新发补充氧疗持续时间,反映急性肺损伤恢复。
  • 在高新发低氧血症人群中,OFDs检验效能通常高于死亡等结局。
  • OFDs为ACTIV-4 Host Tissue平台主要结局,用于COVID-19住院患者。

核心结论

  • OFDs是整合死亡与新发补充氧疗持续时间的复合结局,可表征急性肺损伤恢复。
  • 在高新发低氧血症与补充氧疗使用人群中,OFDs捕捉死亡与低氧性肺功能障碍两个患者中心结局。
  • 检测OFDs差异的检验效能通常高于死亡与无呼吸机天数等其他临床试验结局。

研究设计与样本

  • 本文为方法学阐述,提出OFDs的标准化定义与分析方法及样本量计算框架。
  • OFDs为ACTIV-4 Host Tissue平台的主要结局,该平台评估住院COVID-19伴新发低氧血症成人的宿主反应靶向治疗。

主要发现

  • 过度依赖死亡作为主要结局可能限制可开展试验的范围,且大样本量通常为死亡结局所必需。
  • 仅关注死亡未能认识到降低发病率对患者生活的重要性。
  • COVID-19大流行凸显了快速高效试验严格评估急性肺损伤住院患者新疗法的需求。

关键数值与推荐

  • OFDs为死亡与新发补充氧疗持续时间的复合结局。
  • OFDs设计用于新发低氧血症与补充氧疗高流行人群的急性肺损伤恢复表征。

临床怎么用

  • 在急性肺损伤临床试验中可采用OFDs作为主要结局,尤其适用于新发低氧血症高流行人群。
  • 使用OFDs时需按本文提出的标准化方法定义与分析,并参考其框架进行样本量计算。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mortality historically has been the primary outcome of choice for acute and critical care clinical trials. However, undue reliance on mortality can limit the scope of trials that can be performed. Large sample sizes are usually needed for trials powered for a mortality outcome, and focusing solely on mortality fails to recognize the importance that reducing morbidity can have on patients' lives. The COVID-19 pandemic has highlighted the need for rapid, efficient trials to rigorously evaluate new therapies for hospitalized patients with acute lung injury. Oxygen-free days (OFDs) is a novel outcome for clinical trials that is a composite of mortality and duration of new supplemental oxygen use. It is designed to characterize recovery from acute lung injury in populations with a high prevalence of new hypoxemia and supplemental oxygen use. In these populations, OFDs captures two patient-centered consequences of acute lung injury: mortality and hypoxemic lung dysfunction. Power to detect differences in OFDs typically is greater than that for other clinical trial outcomes, such as mortality and ventilator-free days. OFDs is the primary outcome for the Fourth Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV-4) Host Tissue platform, which evaluates novel therapies targeting the host response to COVID-19 among adults hospitalized with COVID-19 and new hypoxemia. This article outlines the rationale for use of OFDs as an outcome for clinical trials, proposes a standardized method for defining and analyzing OFDs, and provides a framework for sample size calculations using the OFD outcome.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Moskowitz A, Shotwell MS, Gibbs KW, et al. Oxygen-Free Days as an Outcome Measure in Clinical Trials of Therapies for COVID-19 and Other Causes of New-Onset Hypoxemia. Chest. 2022. PMID: 35504307. doi:10.1016/j.chest.2022.04.145

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。